Log on / register
Feedback | Support | My details
Open AccessData Note

The Alternative Splicing Mutation Database: a hub for investigations of alternative splicing using mutational evidence

Jason M Bechtel1 email, Preeti Rajesh2,3 email, Irina Ilikchyan4 email, Ying Deng5 email, Pankaj K Mishra2 email, Qi Wang5 email, Xiaochun Wu2 email, Kirill A Afonin4 email, William E Grose2 email, Ye Wang4 email, Sadik Khuder1,6 email and Alexei Fedorov1,6 email

1Program in Bioinformatics and Proteomics/Genomics, University of Toledo Health Science Campus, Toledo, Ohio 43614, USA

2Dept. of Medical Microbiology and Immunology, University of Toledo Health Science Campus, Toledo, Ohio 43614, USA

3Dept. of Basic Pharmaceutical Sciences, South Carolina College of Pharmacy, University of South Carolina, Columbia, South Carolina 29208, USA

4Department of Biological Sciences, Bowling Green State University, Bowling Green, Ohio 43403, USA

5College of Engineering, University of Toledo, Toledo, Ohio 43606, USA

6Dept. of Medicine, University of Toledo Health Science Campus, Toledo, Ohio 43614, USA

author email corresponding author email

BMC Research Notes 2008, 1:3doi:10.1186/1756-0500-1-3

Published: 26 February 2008

Abstract

Background

Some mutations in the internal regions of exons occur within splicing enhancers and silencers, influencing the pattern of alternative splicing in the corresponding genes. To understand how these sequence changes affect splicing, we created a database of these mutations.

Findings

The Alternative Splicing Mutation Database (ASMD) serves as a repository for all exonic mutations not associated with splicing junctions that measurably change the pattern of alternative splicing. In this initial published release (version 1.2), only human sequences are present, but the ASMD will grow to include other organisms, (see Availability and requirements section for the ASMD web address).

This relational database allows users to investigate connections between mutations and features of the surrounding sequences, including flanking sequences, RNA secondary structures and strengths of splice junctions. Splicing effects of the mutations are quantified by the relative presence of alternative mRNA isoforms with and without a given mutation. This measure is further categorized by the accuracy of the experimental methods employed. The database currently contains 170 mutations in 66 exons, yet these numbers increase regularly.

We developed an algorithm to derive a table of oligonucleotide Splicing Potential (SP) values from the ASMD dataset. We present the SP concept and tools in detail in our corresponding article.

Conclusion

The current data set demonstrates that mutations affecting splicing are located throughout exons and might be enriched within local RNA secondary structures. Exons from the ASMD have below average splicing junction strength scores, but the difference is small and is judged not to be significant.


© 1999-2008 BioMed Central Ltd unless otherwise stated